MacroGenics | MGNX - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.27B 538M 2026-03
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Biogen USD 1.96B 69.6M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Genmab DKK 798M 235M 2025-12
Geron USD 58.8M 2.31M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
J&J USD 17.44B 1.53B 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 18.17B 8.01B 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Xencor USD 81.86M 13.35M 2025-12